Physician Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Astralis, Ltd.

Drug maker reports loss of $0.02 per share

For the 3 months ended March 31, 2005, the company recorded a net loss of $1.68 million to common stockholders, or $ 0.02 per share. The company, which is a development stage entity, had no revenue during this period.

Total shareholders' equity as of March 31, 2005, was $.79 million and the company had a cash balance totaling $ 1.01 million as of March 31, 2005.

Research and development expenses for the first quarter 2005 amounted to $1.09 million including $.86 million relating to the phase II study for Psoraxine.

This article was prepared by...

• View Other Issues of Physician Law Weekly
  
• View Other NewsRx Publications